Mingyu Zhang

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 4

Top Topics

End Stage Renal Disease

High Throughput

Natural Killer Cells

Top Venues

Cancer gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Xisong Liang, Zeyu Wang, Ziyu Dai, Hao Zhang, Jian Zhang, Peng Luo, Zaoqu Liu, Zhixiong Liu, Kui Yang, Quan Chen, Mingyu Zhang
Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. Cancer gene therapy 30 (3) (2022)
Xisong Liang, Zeyu Wang, Ziyu Dai, Hao Zhang, Jian Zhang, Peng Luo, Zaoqu Liu, Zhixiong Liu, Kui Yang, Quan Chen, Mingyu Zhang
Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. Cancer gene therapy (2022)
Xisong Liang, Zeyu Wang, Ziyu Dai, Hao Zhang, Jian Zhang, Peng Luo, Zaoqu Liu, Zhixiong Liu, Kui Yang, Quan Chen, Mingyu Zhang
Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. Cancer gene therapy 30 (3) (2022)
Xisong Liang, Zeyu Wang, Ziyu Dai, Hao Zhang, Jian Zhang, Peng Luo, Zaoqu Liu, Zhixiong Liu, Kui Yang, Quan Chen, Mingyu Zhang
Glioblastoma glycolytic signature predicts unfavorable prognosis, immunological heterogeneity, and ENO1 promotes microglia M2 polarization and cancer cell malignancy. Cancer gene therapy 30 (3) (2022)